Company intelligence / Profile preview

Envisagenics

New York, New York, United Statesenvisagenics.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Envisagenics leverages its proprietary SpliceCore® AI/ML platform to discover novel therapeutic targets by analyzing disease-specific RNA splicing errors. The company collaborates with academic institutions and biopharma partners to validate its approach. Its pipeline focuses on developing highly specific RNA therapeutics for oncology, neurodegenerative, and genetic diseases. As of mid–2024, the company remains preclinical with no reported clinical trial results or approved products.

Therapeutic areas: OncologyRare DiseasesNeurologyOther
Modalities: RNA therapeutics (including antisense oligonucleotides and splicing modulators)
Industry: Biotech

Drug pipeline

4 assets

ENV-375

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with academic institutions such as Cold Spring Harbor Laboratory; partnerships with biopharma companies for proof-of-concept studies.

Beyond the preview

Go deeper on Envisagenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Envisagenics.

Explore the full profile